Welcome to our dedicated page for Axon Enterprise SEC filings (Ticker: AXON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Axon Enterprise, Inc. (NASDAQ: AXON), a public safety technology company that reports under the Exchange Act. Through these filings, investors can review how Axon describes its Connected Devices and Software & Services segments, its public safety operating system strategy and its capital structure.
Axon uses periodic and current reports, including Forms 10-K, 10-Q and 8-K, to disclose financial performance, segment results, annual recurring revenue metrics and material events. Recent Form 8-K filings referenced in company communications include shareholder letters detailing quarterly revenue growth, updates to revenue outlook, and additional information on the performance of Software & Services and Connected Devices. Other 8-K filings describe governance changes, such as the appointment of new directors, and capital markets activity, including privately negotiated exchanges of 0.50% convertible senior notes due 2027 for cash and common stock, and a notice of redemption for these notes with terms for redemption and conversion.
On Stock Titan, Axon’s SEC filings are updated in near real time as documents are posted to the EDGAR system. AI-powered summaries help explain lengthy filings by highlighting key topics such as segment performance, annual recurring revenue, future contracted bookings, note exchanges and redemptions, and other material disclosures. Users can also review insider and executive-related filings, such as Forms 3, 4 and 5, to track equity awards, stock transactions and governance developments.
Whether you are analyzing Axon’s financial condition, understanding its use of convertible notes, or reviewing disclosures about acquisitions and emergency communications strategy, this filings page offers a centralized view of AXON’s regulatory history with AI tools that surface the most important information from each document.
Axon Enterprise, Inc. officer Elizabeth Reid Coughlin, the company's Chief Human Officer, filed an initial ownership report showing her beneficial holdings of the company’s common stock as of January 1, 2026. She reports beneficial ownership of 39,468.65 shares of common stock held directly.
This amount includes 10,287.65 restricted stock units from four time‑vested awards under the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan, with scheduled vesting in installments on specified dates from March 3, 2026 through November 30, 2028. It also includes 6,818 performance-based restricted stock units granted for achievement of tranche 3 of the 2024 eXponential Stock Plan, which are scheduled to vest on June 1, 2026, followed by a minimum holding period extending until at least December 31, 2030 or the vesting of a subsequent tranche. In addition, the holdings include 22,363 shares issued from prior vesting of restricted stock units before January 1, 2026.
Axon Enterprise chief executive Patrick W. Smith reported a planned sale of company stock under a Rule 10b5-1 trading plan. On January 7, 2026, he sold Axon common shares in a series of open-market transactions at weighted average prices generally around $610–$625 per share, each coded as a sale of non-derivative common stock. The filing states these trades were executed pursuant to a Rule 10b5-1 plan adopted on May 12, 2025, indicating the sales were pre-arranged.
After completing the reported transactions, Smith directly beneficially owned 3,100,997 shares of Axon common stock. The prices disclosed for each line reflect weighted averages for multiple trades within specified price ranges, and Smith has undertaken to provide detailed trade breakdowns to regulators, the issuer, or shareholders on request.
AXON filed a Rule 144 notice indicating that insider Patrick W. Smith plans to sell 10,000 shares of common stock through UBS Financial Services on Nasdaq, with an aggregate market value of 6,197,900.00.
The shares to be sold were acquired on 11/15/2021 via an option exercise paid in cash. The notice also reports that over the past three months Smith sold three separate blocks of 10,000 shares each, with gross proceeds of 5,519,164.00, 7,137,353.00, and 5,910,426.00, respectively.
Axon Enterprise, Inc. has given formal notice that it will redeem all of its outstanding 0.50% convertible senior notes due 2027 on February 10, 2026. The notes will be redeemed at 100% of their principal amount, plus accrued and unpaid interest up to, but excluding, the redemption date.
Noteholders are allowed to convert their notes into a mix of cash and Axon common stock at any time until the close of business on February 6, 2026. Axon will pay cash for up to the principal amount (including any cash in place of fractional shares) and will deliver shares of common stock for any conversion value above principal. The final settlement amounts for conversions will be calculated over a 30 trading day observation period from December 24, 2025 through February 6, 2026, and paid or delivered on February 10, 2026.
Axon Enterprise, Inc. reported an insider equity award to its Chief Accounting Officer, Jennifer H. Mak. On 12/15/2025, she acquired 1,359.824 shares of common stock at a price of $0, reported as an acquisition under a company equity plan. Following this transaction, she beneficially owned 14,873.824 shares of Axon common stock in total.
The filing explains that these are time-vested restricted stock units granted under the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan. The units are scheduled to vest in four equal installments of 339.956 shares each on March 3, 2028, May 31, 2028, August 31, 2028, and November 30, 2028, aligning her compensation with the company’s longer-term performance.
Axon Enterprise, Inc. updated a prior report to detail the closing of separate, privately negotiated exchange transactions with certain holders of its 0.50% Convertible Senior Notes due 2027. On December 16, 2025, holders exchanged $196,854,000 in aggregate principal amount of these notes for a combination of $196,859,243.77 in cash, which included accrued interest and cash in lieu of fractional shares, and 526,802 shares of Axon common stock. The update clarifies the total amount of notes included, reflecting an additional $19,000,000 principal amount from an exchange agreement entered into on December 15, 2025.
Axon Enterprise director Caitlin E. Kalinowski reported an insider ownership change involving a charitable gift of company stock. On 12/15/2025, she disposed of 180 shares of Axon Enterprise common stock in a transaction coded "G," which is described as a gift to a charitable donor-advised fund at a reported price of $0 per share. Following this transaction, she directly beneficially owns 4,515 shares of Axon Enterprise common stock.
Axon Enterprise's COO and CFO, Brittany Bagley, reported selling 2,000 shares of common stock on 12/11/2025 at a price of $580 per share.
Following this sale, she beneficially owns 103,501 shares directly, indicating she continues to hold a substantial stake in Axon while disposing of a small portion of her holdings.
Axon Enterprise director Jeri Williams reported selling small amounts of company common stock. On December 4, 2025, Williams sold 65 shares at a weighted average price of
After these transactions, Williams directly beneficially owned 1,316 shares of Axon Enterprise common stock. Each sale was executed in multiple trades within narrow price ranges, and full trade details are available on request to the company, the SEC staff, or security holders.
Axon Enterprise, Inc. reported an equity award update for its President, Joshua Isner. On 11/13/2025, he acquired 67,910 shares of common stock at a price of $0, increasing his directly held beneficial ownership to 306,289 shares. These shares relate to performance-based restricted stock units (XSUs) originally granted on December 22, 2023 under the Axon Enterprise, Inc. 2024 eXponential Stock Plan.
The reported tranche of XSUs had its performance conditions certified as achieved by the company’s Compensation Committee on 11/13/2025 and is scheduled to vest on June 1, 2026, subject to Mr. Isner’s continued employment through that date. After vesting, the delivered shares will be subject to a minimum holding period until the earlier of December 31, 2030 or the vesting date of a subsequent XSU tranche, excluding any shares withheld or sold to cover taxes.